LAKE FOREST, Ill., Nov. 17, 2014 /PRNewswire/ -- The board of
directors and employees of Hospira, Inc. (NYSE: HSP) today
expressed their deepest sorrow over the loss of Connie R.
Curran, R.N., Ed. D, one of the
company's founding board members. Dr. Curran had served as a member of the Hospira
Board since 2004, providing invaluable contributions to the
business through her strategic leadership, exceptional command of
the healthcare industry and shared passion for the company's
commitment to putting patients first.
"Our hearts are heavy with the loss of our dear friend and sage
advisor," said John C. Staley,
chairman, Hospira. "Connie had a rare combination of brilliance,
humor, humility and passion that touched every person fortunate
enough to cross her path. We were privileged to have known and
worked with such a remarkable woman and mourn our loss."
Added F. Michael Ball, Hospira's
chief executive officer, "With talents and achievements too
numerous to count, it's Connie's heart, generosity and vibrant
spirit that made her a unique and powerful force – from the board
room to the patient bedside and everywhere in between. Connie made
everyone she interacted with feel special and richer for the
experience, and we have all benefited from our association with her
both personally and professionally -- she will be greatly
missed."
To honor Dr. Curran's legacy
and wishes, the Hospira Foundation is directing a donation to the
Breast Cancer Research Foundation.
About Hospira
Hospira, Inc. is the world's leading provider of injectable
drugs and infusion technologies, and a global leader in
biosimilars. Through its broad, integrated portfolio, Hospira is
uniquely positioned to Advance Wellness™ by improving patient and
caregiver safety while reducing healthcare costs. The company is
headquartered in Lake Forest,
Ill., and has approximately 19,000 employees. Learn more at
www.hospira.com.
Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains, or may contain, forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Hospira cautions that these forward-looking
statements are subject to risks and uncertainties that may cause
actual results to differ materially from those indicated in the
forward-looking statements. Economic, competitive, governmental,
regulatory, legal, technological, manufacturing, supply, quality
and other factors that may affect Hospira's operations, and may
cause actual results to be materially different from expectations
also include the risks, uncertainties and factors discussed under
the headings "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in
Hospira's latest Annual Report on Form 10-K and subsequent Forms
10-Q, filed with the Securities and Exchange Commission, which are
incorporated by reference. Hospira undertakes no obligation to
release publicly any revisions to forward-looking statements as a
result of subsequent events or developments, except as required by
law.
SOURCE Hospira, Inc.